Skip to main content
All Posts By

admin

Imrs

Building and sustaining public trust in science – The Washington Post

By News Archive

ImrsThe coronavirus pandemic has underlined the value of clearly communicating scientific data, public health guidance and risk factors amidst uncertainty. On Tuesday, Dec. 6 at 9:00 a.m. ET, join Washington Post Live for a series of conversations with Francis S. Collins, former director of the National Institutes of Health, Katrine Wallace, an epidemiologist from the University of Illinois Chicago School of Public Health, and Kurt Newman, president and CEO of Children’s National Hospital, about strengthening trust in science across society, countering misinformation and navigating heightened political divisions.

Image: https://www.washingtonpost.com/

Read More
1668700627043

Apply – virginia catalyst – Grant Round 14 Now Open!

By News Archive

1668700627043October 6, 2022 – Now accepting Letters of Intent (LOI) for Grant Round 14 

Dec 7, 2022   5:00 PM EDT  Deadline to submit LOI for consideration in Grant Round 14

December 16, 2022   Invitation to submit a full application will be sent to Applicant Teams whose LOI meets funding criteria

February 2, 2023  5:00 PM Eastern  Deadline to submit full application for Grant Round 14

February 24, 2023  Invitation to present proposal in person to our Project Management and Oversight Panel (PMOP) will be sent to the top 8 applicant teams as determined by scoring and ranking of applications

Week of March 13, 2023  Proposal Presentations 

Week of March 20, 2023 Virginia Board of Directors final funding decision for Grant Round 14 March 2023  Grant Round 14 Awardees announced

 

Read More
HayStack-Logo

Baltimore biotech Haystack Oncology raises $56M, plans move to City Garage

By News Archive

HayStack-LogoThe Johns Hopkins University researchers behind two of Baltimore’s most successful biotech firms have founded a new company that has now raised $56 million to create a new diagnostic tool for cancer.

Haystack Oncology plans to use the funding from its series A round to kickstart a move into a large lab inside of City Garage in Port Covington, which was recently renamed Baltimore Peninsula. The company also plans to invest in more clinical trials to get additional data to support the effectiveness of Haystack’s cancer detection blood test. The 50-person company, currently based at Hopkins’ FastForwardU, plans to have a commercial launch in 2023.

Read More
Smiling businessman in the city using tablet 2022 11 06 23 01 26 utc

Why the life sciences sector is heading for the city

By News Archive

Smiling businessman in the city using tablet 2022 11 06 23 01 26 utcFrom New York to Paris and London, life sciences companies are being drawn to parts of town often more synonymous with financial services. In London, the Canary Wharf Group and Kadans Science Partner are jointly developing Europe’s largest commercial laboratory building. Life science organization Genomics England will move in later this year, joined by a mix of startups, academics, clinicians and established pharmaceutical companies.

 

Read More
Scientist working in the hospital with microscope 2022 03 07 22 34 56 utc

Rockville Expansion | Merck KGaA, Darmstadt, Germany

By News Archive

Scientist working in the hospital with microscope 2022 03 07 22 34 56 utcMerck KGaA, Darmstadt, Germany, a leading science and technology company, invests more than € 290 million in its biosafety testing capacity at Rockville, Maryland, USA. This will significantly increase the company’s ability to conduct biosafety testing and analytical development services. Biosafety testing and analytical development are critical and fundamental requirements of the drug development and commercialization process to ensure the safety of medicines. Global demand for these services is growing at a double-digit rate.

 

Read More
BHCR 2022 Q3 News Recap

BioHealth Capital Region 2022 Q3 News Recap – Keeping Up the Momentum · BioBuzz

By News Archive

BHCR 2022 Q3 News RecapA few of BioBuzz’s favorite stories from late summer/early fall Over the past several months, life sciences companies across the BioHealth Capital Region showcased their innovative capabilities and pipeline development program. BioBuzz takes a look back at five key events that took place in the third quarter.

BioFactura Moves Forward with Stelara Biosimilar

Frederick, Maryland-based BioFactura is beginning to see the fruits of its labors with the development of ustekinumab (BFI-751), its biosimilar for Janssen’s Stelara. In October, the company announced Phase 1 data that showed pharmacokinetic comparability to the comparison drug.

The company also reported there were no marked differences in the safety and tolerability profile for subjects receiving ustekinumab. BioFactura intends to conduct a confirmatory safety and efficacy study in patients to pave the way for global registration.

Image: https://biobuzz.io/

Read More
Millipore Sigma Logo

Maryland’s Governor Hogan Announces MilliporeSigma Expanding Biosafety Testing In Montgomery County, Adding 500 New Jobs

By News Archive

Millipore Sigma LogoBALTIMORE, MD (November 16, 2022) — Governor Larry Hogan today announced that MilliporeSigma, an international biosciences company, is growing its presence in Montgomery County with a $286 million investment to expand its biosafety testing capacity.

The company, known locally as BioReliance Corporation, currently has five locations in Rockville and is planning to consolidate in a new 250,000-square-foot facility at 9820 Darnestown Road at the Alexandria Center® at Traville Gateway campus, which is being developed and operated by Alexandria Real Estate Equities, Inc. MilliporeSigma will maintain one additional facility at 9630 Medical Center Drive and will retain at least 600 full-time employees during the expansion, while creating more than 500 new jobs over the next four years.

Read More
Roundcube Webmail NextCureSLCB jpg

NextCure and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody Drug Conjugates

By News Archive

Roundcube Webmail NextCureSLCB jpgBELTSVILLE, Md. and DAEJEON, South Korea, Nov. 15, 2022 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC) and LegoChem Biosciences, Inc. (LCB, KOSDAQ: 141080) today announced a collaboration and co-development agreement focused on generating a B7-H4 antibody drug conjugate (ADC) and options for two additional targets. The B7-H4 ADC will utilize NextCure’s B7-H4 antibody and LCB’s ConjuAllTM ADC technology.

Under the terms of the agreement, both parties will equally share the costs to develop the molecules and profits on commercialized products. The parties will utilize their respective product development capabilities to generate the B7-H4 ADC and advance it to the clinic. In addition, there are options for the parties to nominate two additional targets for ADC development beyond B7-H4.

Read More
Brainbox Logo

BRAINBox Solutions Enrolls 1000th Patient in Pivotal, HeadSMART II Clinical Study of BRAINBox TBI Concussion Diagnostic and Prognostic Test

By News Archive

Brainbox LogoRICHMOND, Va., Nov. 14, 2022 /PRNewswire/ — BRAINBox Solutions today announced that the company has enrolled the 1,000th patient in the pivotal, HeadSMART II study of its concussion diagnostic and prognostic test, BRAINBox TBI. The multi-national, multi-site, trial is designed to support an application for regulatory clearance by the U.S. FDA.

“We are developing the BRAINBox TBI (Traumatic Brain Injury) test as the first objective test to aid in the diagnosis of concussion and to provide an assessment of the risk of post-concussive symptoms,” said Donna Edmonds, BRAINBox Solutions’ CEO. “We are now in the home stretch of this very important study for the field. We believe the test has great potential to change clinical practice in the diagnosis and management of concussion and will define for the first time, objective diagnostic criteria for this condition, termed Acute Traumatic Encephalopathy (ATE). As such, the trial has been rigorously designed in collaboration with leading experts in traumatic brain injury and emergency medicine. The study evaluates patients in multiple settings and includes state of the art expert adjudication panels.”

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.